Viridian Therapeutics, Inc./DE Payments to Acquire Debt Securities, Available-for-sale
Viridian Therapeutics, Inc./DE (VRDN) reported Payments to Acquire Debt Securities, Available-for-sale of $469.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $378.65M, a 579.14% increase year-over-year.
- Viridian Therapeutics, Inc./DE payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $91.32M, a 28.18% increase year-over-year.
- Viridian Therapeutics, Inc./DE payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $438.19M, a 141.06% increase year-over-year.
- Viridian Therapeutics, Inc./DE payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $14.09M, a 93.83% decline year-over-year.
- Viridian Therapeutics, Inc./DE payments to acquire debt securities, available-for-sale for fiscal 2025 was $579.28M, a 16.66% decline from fiscal 2024.
- Viridian Therapeutics, Inc./DE payments to acquire debt securities, available-for-sale for fiscal 2024 was $695.07M, a 70.41% increase from fiscal 2023.
- Viridian Therapeutics, Inc./DE payments to acquire debt securities, available-for-sale for fiscal 2023 was $407.88M, a 82.69% increase from fiscal 2022.
- Viridian Therapeutics, Inc./DE payments to acquire debt securities, available-for-sale for fiscal 2022 was $223.26M, a 18.49% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $378.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $469.98M 10-Q · filed 2026-08-06 | $908.17M derived: sum of 3 quarters · filed 2026-08-06 | $922.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $91.32M 10-Q · filed 2026-05-05 | $529.51M derived: sum of 2 quarters · filed 2026-05-05 | $543.60M derived: sum of 3 quarters · filed 2026-05-05 | $599.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $438.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $452.28M derived: sum of 2 quarters · filed 2026-02-26 | $508.03M derived: sum of 3 quarters · filed 2026-08-06 | $579.28M 10-K · filed 2026-02-26 |
| 2025-09-30 | $14.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $69.84M derived: sum of 2 quarters · filed 2026-08-06 | $141.08M 10-Q · filed 2025-11-05 | $322.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $55.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $127.00M 10-Q · filed 2026-08-06 | $308.78M derived: sum of 3 quarters · filed 2026-08-06 | $537.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $71.24M 10-Q · filed 2026-05-05 | $253.02M derived: sum of 2 quarters · filed 2026-05-05 | $481.44M derived: sum of 3 quarters · filed 2026-05-05 | $540.70M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $181.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $410.20M derived: sum of 2 quarters · filed 2026-02-26 | $469.46M derived: sum of 3 quarters · filed 2026-02-26 | $695.07M 10-K · filed 2026-02-26 |
| 2024-09-30 | $228.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $287.68M derived: sum of 2 quarters · filed 2025-11-05 | $513.29M 10-Q · filed 2025-11-05 | $785.78M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $59.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $284.87M 10-Q · filed 2025-08-06 | $557.36M derived: sum of 3 quarters · filed 2026-02-26 | $607.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $225.61M 10-Q · filed 2025-05-06 | $498.10M derived: sum of 2 quarters · filed 2026-02-26 | $548.15M derived: sum of 3 quarters · filed 2026-02-26 | $556.21M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $272.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $322.54M derived: sum of 2 quarters · filed 2026-02-26 | $330.60M derived: sum of 3 quarters · filed 2026-02-26 | $407.88M 10-K · filed 2026-02-26 |
| 2023-09-30 | $50.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $58.10M derived: sum of 2 quarters · filed 2024-11-12 | $135.38M 10-Q · filed 2024-11-12 | $353.46M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $8.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $85.34M 10-Q · filed 2024-08-08 | $303.41M derived: sum of 3 quarters · filed 2025-03-03 | $303.41M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $77.28M 10-Q · filed 2024-05-08 | $295.35M derived: sum of 2 quarters · filed 2025-03-03 | $295.35M derived: sum of 3 quarters · filed 2025-03-03 | $295.35M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $218.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $218.07M derived: sum of 2 quarters · filed 2025-03-03 | $218.07M derived: sum of 3 quarters · filed 2025-03-03 | $223.26M 10-K · filed 2025-03-03 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $5.19M 10-Q · filed 2023-11-13 | $108.08M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.19M 10-Q · filed 2023-08-08 | $108.08M derived: sum of 3 quarters · filed 2024-02-27 | $126.24M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $5.19M 10-Q · filed 2023-05-10 | $108.08M derived: sum of 2 quarters · filed 2024-02-27 | $126.24M derived: sum of 3 quarters · filed 2024-02-27 | $136.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $102.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $121.05M derived: sum of 2 quarters · filed 2024-02-27 | $131.78M derived: sum of 3 quarters · filed 2024-02-27 | $188.43M 10-K · filed 2024-02-27 |
| 2021-09-30 | $18.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $28.89M derived: sum of 2 quarters · filed 2022-11-14 | $85.55M 10-Q · filed 2022-11-14 | $167.35M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $10.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $67.38M 10-Q · filed 2022-08-15 | $149.19M derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $56.65M 10-Q · filed 2022-05-13 | $138.46M derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $81.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $81.81M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |